

## **Valneva Announces the Publication of its Registration Document**

**Lyon (France), June 17, 2015** – Valneva SE (“Valneva”), a leading pure-play vaccines biotech company, announces today that it has filed its registration document (“document de référence”), containing its 2014 annual financial report, with the French market regulator Autorité des marchés financiers (AMF) under the filing number D.15-0614.

The document is available on the Company’s corporate website ([www.valneva.com](http://www.valneva.com)) in the “Investors and Media” section under the heading “Registration document” and on the AMF website ([www.amf-france.org](http://www.amf-france.org)). A hard copy of the document, which contains the Company’s complete audited financial statements, may be obtained free of charge upon request at the following address: 6 rue Alain Bombard, 44800 Saint Herblain.

### **About Valneva SE**

Formed in 2013 through the merger of Intercell AG and Vivalis SA, Valneva is a biotechnology company specialized in the development, manufacture and commercialization of innovative vaccines with a mission to protect people from infectious diseases. The Company seeks financial returns through focused R&D investments in promising product candidates and growing financial contributions from commercial products, striving towards financial self-sustainability.

Valneva’s portfolio includes two commercial vaccines for travelers: one for the prevention of Japanese encephalitis (IXIARO®) and the second (DUKORAL®) indicated for active immunization against Cholera and, in some countries, prevention of Travelers’ Diarrhea caused by ETEC (Enterotoxigenic Escherichia coli). The Company has proprietary vaccines in development including candidates against Pseudomonas aeruginosa, Clostridium difficile and Lyme Borreliosis. A variety of partnerships with leading pharmaceutical companies complement the Company’s value proposition and include vaccines being developed using Valneva’s innovative and validated technology platforms (EB66® vaccine production cell line, IC31® adjuvant).

Valneva has its registered seat in Lyon, France, is listed on Euronext-Paris and the Vienna Stock Exchange and operates out of France, Austria, Scotland and Sweden with approximately 400 employees. More information is available at [www.valneva.com](http://www.valneva.com).

[www.valneva.com](http://www.valneva.com)

Contact :  
Laetitia Bachelot-Fontaine  
Head of Investor Relations  
& Corporate Communications  
T +02-28-07-14-19  
M +33 (0)6 4516 7099  
[Communications@valneva.com](mailto:Communications@valneva.com)

Teresa Pinzolit  
Corporate Communications Specialist  
T +43-1-206 20-1116  
M +43-676-84 55 67 357

